Dr. Robert Gish is the Medical Advisor to Helio Genomics and the Medical Director of the Hepatitis B Foundation and is looking for answers to questions related to who is most at risk for liver cancer. He is also working to improve blood testing to diagnose liver cancer earlier by looking for tumor material that shows methylated DNA changes.
Robert explains, "So, one of the biggest messages I would have is the deficiency in surveillance for liver cancer. Screening is the first test, and surveillance is ongoing testing. Some people get confused with the word screening, unfortunately. We are not testing patients for liver cancer anywhere near what we should. Probably 20%, one out of five, people are getting proper surveillance when they're at risk for liver cancer."
"Let's talk about at risk. That's a second message. Identifying people with risk, which is cirrhosis, 80%, 85% of people with liver cancer have cirrhosis, is also inadequate. We need to teach people how to find out if somebody has cirrhosis without doing a liver biopsy. We have great tools, but the education of the medical community and patient community needs to be much more robust, in my opinion."
@HepBFoundation #HelioGenomics #CancerDetection #LiverCancer #BeatCancerEarly #Stage4NoMore
hepb.org
heliogenomics.com
Download the transcript here
Empowered Patient Podcast